fbpx

molecules of the month

BMS-986144

pan-genotype HCV NS3/4A protease inhibitor

proj. oral QD dosing, well-tolerated in rodent

deuteration reduced CYP TDI

J. Med. Chem., Nov. 23, 2020

Bristol-Myers Squibb, NJ + MA + CT + IN

BMS-986144
1 min read

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: